Header Logo

Connection

Johnny Mahlangu to Humans

This is a "connection" page, showing publications Johnny Mahlangu has written about Humans.
Connection Strength

3,239
  1. Extension Study With rVIII-SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A. Haemophilia. 2025 Mar; 31(2):214-223.
    View in: PubMed
    Score: 0,074
  2. Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies. Expert Rev Hematol. 2024 Oct; 17(10):741-748.
    View in: PubMed
    Score: 0,072
  3. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
    View in: PubMed
    Score: 0,070
  4. Diagnosis and treatment challenges in lower resource countries: State-of-the-art. Haemophilia. 2024 Apr; 30 Suppl 3:78-85.
    View in: PubMed
    Score: 0,069
  5. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023 02 23; 388(8):694-705.
    View in: PubMed
    Score: 0,064
  6. Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 01; 200(2):240-248.
    View in: PubMed
    Score: 0,063
  7. Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis. J Clin Pathol. 2023 Aug; 76(8):555-560.
    View in: PubMed
    Score: 0,063
  8. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. Br J Haematol. 2023 01; 200(2):229-239.
    View in: PubMed
    Score: 0,062
  9. Prophylaxis is the new standard of care in patients with haemophilia. S Afr Med J. 2022 05 31; 112(6):405-408.
    View in: PubMed
    Score: 0,061
  10. Emicizumab state-of-the-art update. Haemophilia. 2022 May; 28 Suppl 4:103-110.
    View in: PubMed
    Score: 0,061
  11. An update of the current pharmacotherapeutic armamentarium for hemophilia A. Expert Opin Pharmacother. 2022 Jan; 23(1):129-138.
    View in: PubMed
    Score: 0,058
  12. Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B. Haemophilia. 2021 Jul; 27(4):574-580.
    View in: PubMed
    Score: 0,057
  13. Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors. Haemophilia. 2021 Mar; 27(2):221-228.
    View in: PubMed
    Score: 0,056
  14. Immunoglobulin subtyping and quantification in direct antiglobulin test: positive haemolysis in an HIV-prevalent setting. J Clin Pathol. 2022 Feb; 75(2):117-120.
    View in: PubMed
    Score: 0,055
  15. Redefining prophylaxis in the modern era. Haemophilia. 2021 Feb; 27 Suppl 3:21-27.
    View in: PubMed
    Score: 0,053
  16. Requirements to participate in haemophilia clinical trials. Haemophilia. 2020 Apr; 26 Suppl 3:22-25.
    View in: PubMed
    Score: 0,053
  17. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
    View in: PubMed
    Score: 0,053
  18. Capacity building for inherited bleeding disorders in sub-Saharan Africa. Blood Adv. 2019 12 06; 3(Suppl 1):5-7.
    View in: PubMed
    Score: 0,051
  19. Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. S Afr Med J. 2019 Aug 28; 109(9):639-644.
    View in: PubMed
    Score: 0,051
  20. Emicizumab for the prevention of bleeds in hemophilia A. Expert Opin Biol Ther. 2019 08; 19(8):753-761.
    View in: PubMed
    Score: 0,050
  21. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
    View in: PubMed
    Score: 0,049
  22. Analytical Performance of a New Immunoturbidimetric Assay for von Willebrand Factor (VWF) Activity Testing. Clin Lab. 2019 Apr 01; 65(4).
    View in: PubMed
    Score: 0,049
  23. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
    View in: PubMed
    Score: 0,049
  24. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher. 2019 Feb; 34(1):44-50.
    View in: PubMed
    Score: 0,048
  25. rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943.
    View in: PubMed
    Score: 0,048
  26. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
    View in: PubMed
    Score: 0,048
  27. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
    View in: PubMed
    Score: 0,048
  28. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
    View in: PubMed
    Score: 0,047
  29. Emerging therapies for haemophilia - Global perspective. Haemophilia. 2018 May; 24 Suppl 6:15-21.
    View in: PubMed
    Score: 0,046
  30. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 May; 24(3):348-358.
    View in: PubMed
    Score: 0,046
  31. The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):224-229.
    View in: PubMed
    Score: 0,043
  32. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia. 2017 Jan; 23(1):33-41.
    View in: PubMed
    Score: 0,041
  33. TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity. Haemophilia. 2016 Nov; 22(6):873-879.
    View in: PubMed
    Score: 0,041
  34. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76.
    View in: PubMed
    Score: 0,041
  35. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016 Jul; 22 Suppl 5:25-30.
    View in: PubMed
    Score: 0,041
  36. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016 08 04; 128(5):630-7.
    View in: PubMed
    Score: 0,041
  37. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
    View in: PubMed
    Score: 0,040
  38. Diagnosis of iron deficiency anaemia in hospital patients: Use of the reticulocyte haemoglobin content to differentiate iron deficiency anaemia from anaemia of chronic disease. S Afr Med J. 2015 Nov 20; 106(1):53-4.
    View in: PubMed
    Score: 0,039
  39. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity. J Thromb Haemost. 2015 Nov; 13(11):1989-98.
    View in: PubMed
    Score: 0,039
  40. Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia. J Genet Couns. 2015 Dec; 24(6):978-86.
    View in: PubMed
    Score: 0,037
  41. Assessment of outcomes. Haemophilia. 2014 May; 20 Suppl 4:114-20.
    View in: PubMed
    Score: 0,035
  42. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
    View in: PubMed
    Score: 0,034
  43. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.
    View in: PubMed
    Score: 0,030
  44. Haemophilia care in South Africa: 2004-2007 look back. Haemophilia. 2009 Jan; 15(1):135-41.
    View in: PubMed
    Score: 0,024
  45. Guideline for the treatment of haemophilia in South Africa. S Afr Med J. 2008 Feb; 98(2 Pt 2):126-40.
    View in: PubMed
    Score: 0,023
  46. Three-way comparison of methods for the measurement of the erythrocyte sedimentation rate. J Clin Lab Anal. 2008; 22(5):346-52.
    View in: PubMed
    Score: 0,023
  47. Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025 Jan; 31(1):78-86.
    View in: PubMed
    Score: 0,018
  48. The translational gap for gene therapies in low- and middle-income countries. Sci Transl Med. 2024 May 08; 16(746):eadn1902.
    View in: PubMed
    Score: 0,017
  49. Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024 Mar; 30(2):257-266.
    View in: PubMed
    Score: 0,017
  50. Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy. J Thromb Haemost. 2024 May; 22(5):1510-1515.
    View in: PubMed
    Score: 0,017
  51. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024 Apr; 22(4):990-1000.
    View in: PubMed
    Score: 0,017
  52. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
    View in: PubMed
    Score: 0,017
  53. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31; 389(9):783-794.
    View in: PubMed
    Score: 0,017
  54. Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences. Mol Ther. 2023 09 06; 31(9):2561-2565.
    View in: PubMed
    Score: 0,017
  55. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. Blood Adv. 2023 07 11; 7(13):3049-3057.
    View in: PubMed
    Score: 0,017
  56. RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia. J Cell Mol Med. 2023 07; 27(13):1790-1796.
    View in: PubMed
    Score: 0,016
  57. Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.
    View in: PubMed
    Score: 0,016
  58. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study. Lancet Haematol. 2023 Mar; 10(3):e168-e177.
    View in: PubMed
    Score: 0,016
  59. World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. Haemophilia. 2022 09; 28(5):S129-S131.
    View in: PubMed
    Score: 0,015
  60. Haemophilia gene therapy-Update on new country initiatives. Haemophilia. 2022 May; 28 Suppl 4:61-67.
    View in: PubMed
    Score: 0,015
  61. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022 04 28; 139(17):2642-2652.
    View in: PubMed
    Score: 0,015
  62. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022 03 17; 386(11):1013-1025.
    View in: PubMed
    Score: 0,015
  63. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A. Hum Gene Ther. 2022 Apr; 33(7-8):432-441.
    View in: PubMed
    Score: 0,015
  64. A cohort study of the relationship between anaemia, mean corpuscular volume and mortality among a CKD population in South Africa. Afr Health Sci. 2021 Dec; 21(4):1764-1775.
    View in: PubMed
    Score: 0,015
  65. Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. Blood Rev. 2022 05; 53:100907.
    View in: PubMed
    Score: 0,015
  66. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.
    View in: PubMed
    Score: 0,015
  67. Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Nov; 27(6):e772-e775.
    View in: PubMed
    Score: 0,015
  68. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
    View in: PubMed
    Score: 0,015
  69. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost. 2021 08; 19(8):1883-1887.
    View in: PubMed
    Score: 0,014
  70. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
    View in: PubMed
    Score: 0,014
  71. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
    View in: PubMed
    Score: 0,014
  72. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
    View in: PubMed
    Score: 0,014
  73. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021 02 13; 397(10274):630-640.
    View in: PubMed
    Score: 0,014
  74. Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J Thromb Haemost. 2021 01; 19 Suppl 1:32-41.
    View in: PubMed
    Score: 0,014
  75. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost. 2021 01; 19 Suppl 1:21-31.
    View in: PubMed
    Score: 0,014
  76. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. J Thromb Haemost. 2020 11; 18(11):3074-3077.
    View in: PubMed
    Score: 0,014
  77. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
    View in: PubMed
    Score: 0,014
  78. Hepcidin and GDF-15 are potential biomarkers of iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol. 2020 09 29; 21(1):415.
    View in: PubMed
    Score: 0,014
  79. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
    View in: PubMed
    Score: 0,013
  80. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020 Aug; 26 Suppl 6:1-158.
    View in: PubMed
    Score: 0,013
  81. The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Rev. 2021 03; 46:100737.
    View in: PubMed
    Score: 0,013
  82. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study. Haemophilia. 2020 Nov; 26(6):e262-e271.
    View in: PubMed
    Score: 0,013
  83. World Federation of Hemophilia Gene Therapy Registry. Haemophilia. 2020 Jul; 26(4):563-564.
    View in: PubMed
    Score: 0,013
  84. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
    View in: PubMed
    Score: 0,013
  85. Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table. Haemophilia. 2020 May; 26(3):443-449.
    View in: PubMed
    Score: 0,013
  86. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
    View in: PubMed
    Score: 0,013
  87. Improving access to hemophilia care in sub-Saharan Africa by capacity building. Blood Adv. 2019 12 06; 3(Suppl 1):1-4.
    View in: PubMed
    Score: 0,013
  88. Gene and cell therapy in South Africa: Current status and future prospects. S Afr Med J. 2019 Sep 10; 109(8b):12-16.
    View in: PubMed
    Score: 0,013
  89. Patient blood management: A solution for South Africa. S Afr Med J. 2019 Jun 28; 109(7):471-476.
    View in: PubMed
    Score: 0,012
  90. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
    View in: PubMed
    Score: 0,012
  91. Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa. PLoS One. 2018; 13(10):e0204899.
    View in: PubMed
    Score: 0,012
  92. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigmâ„¢ trials. Haemophilia. 2018 Nov; 24(6):911-920.
    View in: PubMed
    Score: 0,012
  93. The predictive value of factor VIII/factor IX levels to define the severity of hemophilia: communication from the SSC of ISTH. J Thromb Haemost. 2018 10; 16(10):2106-2110.
    View in: PubMed
    Score: 0,012
  94. Haemophilia clinical care and research needs: Assessing priorities. Haemophilia. 2018 07; 24(4):e270-e273.
    View in: PubMed
    Score: 0,012
  95. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII. Haemophilia. 2018 May; 24(3):376-384.
    View in: PubMed
    Score: 0,012
  96. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein. Haemophilia. 2018 Jan; 24(1):77-84.
    View in: PubMed
    Score: 0,011
  97. Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
    View in: PubMed
    Score: 0,011
  98. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,011
  99. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Haemophilia. 2017 May; 23(3):392-399.
    View in: PubMed
    Score: 0,011
  100. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017 Feb; 4(2):e75-e82.
    View in: PubMed
    Score: 0,011
  101. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thromb Haemost. 2017 02 28; 117(3):508-518.
    View in: PubMed
    Score: 0,010
  102. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918.
    View in: PubMed
    Score: 0,010
  103. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
    View in: PubMed
    Score: 0,010
  104. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia. 2016 Jul; 22(4):e259-66.
    View in: PubMed
    Score: 0,010
  105. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,010
  106. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigmâ„¢4). Thromb Res. 2016 May; 141:69-76.
    View in: PubMed
    Score: 0,010
  107. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa. Antiviral Res. 2016 Mar; 127:90-8.
    View in: PubMed
    Score: 0,010
  108. Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol. 2015 Dec; 95 Suppl 81:11-21.
    View in: PubMed
    Score: 0,010
  109. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016 Jan; 22(1):72-80.
    View in: PubMed
    Score: 0,010
  110. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
    View in: PubMed
    Score: 0,009
  111. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54.
    View in: PubMed
    Score: 0,009
  112. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015 Sep; 21(5):589-97.
    View in: PubMed
    Score: 0,009
  113. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost. 2014 Nov; 12(11):1788-800.
    View in: PubMed
    Score: 0,009
  114. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6.
    View in: PubMed
    Score: 0,009
  115. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study. Br J Haematol. 2015 Jan; 168(1):124-34.
    View in: PubMed
    Score: 0,009
  116. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014 Aug; 12(8):1244-53.
    View in: PubMed
    Score: 0,009
  117. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia. 2014 Sep; 20(5):687-92.
    View in: PubMed
    Score: 0,009
  118. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
    View in: PubMed
    Score: 0,008
  119. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014 Jan; 12 Suppl 1:s319-29.
    View in: PubMed
    Score: 0,008
  120. Guidelines for the management of hemophilia. Haemophilia. 2013 Jan; 19(1):e1-47.
    View in: PubMed
    Score: 0,008
  121. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan; 10(1):81-9.
    View in: PubMed
    Score: 0,007
  122. Guidelines for the treatment of myelodysplastic syndromes (MDS) in South Africa. S Afr Med J. 2011 Nov 28; 101(12):900-6.
    View in: PubMed
    Score: 0,007
  123. Haemophilia management: time to get personal? Haemophilia. 2011 Sep; 17(5):721-8.
    View in: PubMed
    Score: 0,007
  124. Palindromic-nucleotide substitutions (PNS) of hepatitis C virus genotypes 1 and 5a from South Africa. J Virol Methods. 2011 Aug; 175(2):272-7.
    View in: PubMed
    Score: 0,007
  125. Local reference ranges for full blood count and CD4 lymphocyte count testing. S Afr Med J. 2009 Apr; 99(4):243-8.
    View in: PubMed
    Score: 0,006
  126. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
    View in: PubMed
    Score: 0,006
  127. Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood. 2008 Jun 15; 111(12):5592-600.
    View in: PubMed
    Score: 0,006
  128. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and multiple myeloma in South Africa. Diagn Mol Pathol. 2001 Jun; 10(2):95-9.
    View in: PubMed
    Score: 0,004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.